Close Menu

NEW YORK (GenomeWeb) – Ideally, molecularly informed drug development is supposed to provide pharmaceutical companies with more confidence about how well their therapies work in a specific patient population. But the recent failure of Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) to meet its primary endpoint in a late-stage non-small cell lung cancer trial highlights the pitfalls drugmakers face amid evolving science and imperfect biomarkers.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
May
26
Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.